PCM
NVO

Pavaki Capital Management’s Novo Nordisk NVO Stock Holding History

Pavaki Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$216K Hold
4,500
– – 0.08% 128
2026
Q1 		$165K Hold
4,500
– – 0.07% 127
2025
Q4 		$229K Buy
+4,500
New +$230K 0.09% 101

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Pavaki Capital Management's NVO Position: Q2 2026 in Review

Pavaki Capital Management held its Novo Nordisk (NVO) position steady in Q2 2026 at 4,500 shares worth $216K. The position accounts for 0.08% of the portfolio, ranked #128.

Pavaki Capital Management first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. The position peaked at $229K in Q4 2025. 1,293 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Pavaki Capital Management held 4,500 shares of Novo Nordisk worth $216K as of Q2 2026.
  • Pavaki Capital Management left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.08% of Pavaki Capital Management's portfolio in Q2 2026, its #128 holding.
  • Pavaki Capital Management first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • Pavaki Capital Management's Novo Nordisk position peaked at $229K in Q4 2025.
  • 1,293 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Pavaki Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.